• Home
  • News
  • Coins2Day 500
  • Tech
  • Finance
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
HealthBrainstorm Health

Brainstorm Health: Eclipse Glasses, FDA Approves Pfizer Leukemia Drug, MS Drug Prices

By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
By
Clifton Leaf
Clifton Leaf
and
Sy Mukherjee
Sy Mukherjee
August 18, 2017, 12:00 PM ET

Good morning and happy Friday, readers! This is Sy.

You’ve almost certainly heard about the total solar eclipse set to occur on Monday, August 21. The rare event will be visible in certain regions within more than a dozen states.

But, even with cosmic events, it’s important to put safety first. And when it comes to staring into the sun, that means protecting your eyes with special gear.

Unfortunately, some would-be viewers could have a bit of a problem with that. There have been reports of unauthorized eyewear that have led to recalls and suggestions from county officials in Richland, South Carolina (one of the areas where the eclipse will be visible in its totality) to seek “other options” than the free glasses made available if people feel uncomfortable. There have also been counterfeit pairs sold on Amazon (for which the company has offered refunds).

The American Astronomical Society (AAS) has an approved list of vendors for solar filters.

Read on for the day’s news, and enjoy your weekend!

Sy Mukherjee
@the_sy_guy
[email protected]

DIGITAL HEALTH

IBM to team up with JDRF on type 1 diabetes.  IBM and JDRF, an outfit focused on funding type 1 diabetes research, are teaming up to analyze the factors that may lead to that form of diabetes. The collaboration will involve creating machine learning methods which can analyze mountains of existing type 1 diabetes research in order to figure out risk factors and, hopefully, effective prevention measures.

INDICATIONS

FDA clears Pfizer drug for rare, fast-spreading cancer. The Food and Drug Administration (FDA) has approved Pfizer's Besponsa, a drug to treat a rare and vicious form of leukemia that can quickly kill patients. Besponsa is approved for adults with hard-to-treat or recurring forms of B-cell precursor acute lymphoblastic leukemia (ALL), which nearly 6,000 Americans are diagnosed with each year.(Coins2Day)

House Democrats push for explanation of high MS drug prices. House Democratic lawmakers have launched an investigation into pricing for multiple sclerosis drugs. Seven companies, including pharmaceutical giants like Biogen, Sanofi, Novartis, and Roche, have received letters from the House Government Oversight Committee requesting information on their pricing strategies.(Coins2Day)

REQUIRED READING

The Most Successful CEO of His Generation Steps Down, by Shawn Tully

If You Bought Google At Its IPO Price, Here's How Much Richer You'd Be, by Lucinda Shen

Among Startups, Microsoft and Google Are Giving AWS a Run for Its Money, by Barb Darrow

World Stocks Tumble As Market Hopes in Trump's Reform Agenda Fade, by Coins2Day Editors and Reuters

Produced by Sy Mukherjee
@the_sy_guy
[email protected]

Find past coverage. Sign up for other  Coins2Day newsletters.
About the Authors
By Clifton Leaf
See full bioRight Arrow Button Icon
By Sy Mukherjee
See full bioRight Arrow Button Icon
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.